The 300mg low-dose group showed no maintenance effect: patients falling below ACR20 were 3 of 40 (7.5%) in 600mg, 9 of 36 (25.0%) in 300mg, and 10 of 41 (24.4%) in placebo, meaning the low-dose group was effectively without efficacy.

A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.

600mg 40명 중 3명(7.5%), 300mg 36명 중 9명(25.0%), 위약군 41명 중 10명(24.4%)로 300mg 저용량군과 위약군의 차이가 없어 사실상 저용량군은 유효성이 없는 수준